Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis.
OBJECTIVE
To describe intraocular inflammation due to treatment with intravenous cidofovir dihydrate for cytomegalovirus retinitis.


METHODS
Retrospective cohort.


METHODS
Three university outpatient ophthalmology clinics.


METHODS
All patients treated with intravenous cidofovir therapy before October 31, 1996.


METHODS
Treatment with intravenous cidofovir was given according to standardized protocols. Intraocular inflammation was treated according to the best medical judgment.


METHODS
The presence of new intraocular inflammation, the severity of inflammation, visual acuity, and intraocular pressure.


RESULTS
Eleven cases of iritis (26%) occurred among 43 patients. In 6 cases, the iritis was bilateral. Patients who experienced iritis were more likely to have been previously treated for cytomegalovirus retinitis (P = .03), to be diabetic (P = .05), or to be receiving protease inhibitors (P < .001). Four patients and 15 control subjects had also taken rifabutin (P = .70). The onset of iritis occurred at a mean (+/-SD) of 4.9 +/- 1.8 days after a cidofovir dose and after a mean (+/-SD) of 4.2 +/- 1.6 doses of cidofovir. Six eyes of 4 patients had hypotony. Five eyes of 5 patients had a persistent decrease in visual acuity of at least 2 Snellen lines.


CONCLUSIONS
Acute intraocular inflammation may occur with or without hypotony after intravenous cidofovir therapy, similar to the reactions seen after intravitreous administration. Although the manifestations may be severe, they are manageable with topical corticosteroid therapy in most cases. Cidofovir therapy can be continued in some patients if medical necessity warrants, but recurrent inflammation or permanent hypotony may occur.
Davis
J L
JL
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Fla, USA.
Taskintuna
I
I
Freeman
W R
WR
Weinberg
D V
DV
Feuer
W J
WJ
Leonard
R E
RE
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077404:Cidofovir; D015331:Cohort Studies; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007500:Iritis / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009129:Muscle Tonus / Q000187:drug effects*; D009135:Muscular Diseases / Q000139:chemically induced; D009801:Oculomotor Muscles / Q000187:drug effects*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012173:Retinitis / Q000821:virology*; D012189:Retrospective Studies
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir